Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

This was the stock's third consecutive day of losses.

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

The stock's fall snapped a two-day winning streak.

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede growth. The stock carries a Zacks Rank #4 (Sell) currently. A challenging ...

On Thursday, Piper Sandler initiated coverage on Abbott Laboratories (NYSE:NYSE:ABT) stock, assigning an Overweight rating and setting a price target of $131. The firm highlighted the company's ...

Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes it a top stock to buy and hold for dividend investors -- arguably one of ...